Literature DB >> 11196000

The paradox of normal neuropsychological function in schizophrenia.

W S Kremen1, L J Seidman, S V Faraone, R Toomey, M T Tsuang.   

Abstract

Mounting evidence suggests that compromised neurocognitive function is a core feature of schizophrenia. However, some studies have found neuropsychologically normal schizophrenia patients. To address this apparent contradiction, we blindly rated individual neuropsychological profiles of 75 schizophrenia patients and 91 control participants on the basis of methods developed by L. J. Seidman, S. V. Faraone, W. S. Kremen, J. R. Pepple, M. J. Lyons, and M. T. Tsuang (1993). Almost one-quarter of the patients were classified as neuropsychologically within normal limits (WNL). Despite significantly worse neuropsychological performance, WNL patients had higher estimated premorbid ability than did controls. Compared to a subset of controls matched on overall neuropsychological function, WNL patients had higher estimated premorbid ability and current IQs. Our results favor the view that even neuropsychologically normal schizophrenia patients have compromised cognitive function relative to their presumed expected or premorbid level of intellectual ability.

Entities:  

Mesh:

Year:  2000        PMID: 11196000     DOI: 10.1037//0021-843x.109.4.743

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  45 in total

Review 1.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

2.  Cortical thickness in neuropsychologically near-normal schizophrenia.

Authors:  Derin J Cobia; John G Csernansky; Lei Wang
Journal:  Schizophr Res       Date:  2011-10-07       Impact factor: 4.939

Review 3.  Real-world cognitive--and metacognitive--dysfunction in schizophrenia: a new approach for measuring (and remediating) more "right stuff".

Authors:  Danny Koren; Larry J Seidman; Morris Goldsmith; Phillip D Harvey
Journal:  Schizophr Bull       Date:  2006-01-05       Impact factor: 9.306

Review 4.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

5.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?

Authors:  Philip D Harvey; Alan S Bellack
Journal:  Schizophr Bull       Date:  2009-01-06       Impact factor: 9.306

6.  Brain Structure in Neuropsychologically Defined Subgroups of Schizophrenia and Psychotic Bipolar Disorder.

Authors:  Neil D Woodward; Stephan Heckers
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

Review 7.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

8.  Inclusion of cognitive impairment in the DSM diagnosis of schizophrenia: if not now, when?

Authors:  Siow-Ann Chong
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

9.  Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Authors:  Elsa Gilbert; Chantal Mérette; Valérie Jomphe; Claudia Emond; Nancie Rouleau; Roch-Hugo Bouchard; Marc-André Roy; Thomas Paccalet; Michel Maziade
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-31       Impact factor: 5.270

10.  Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.

Authors:  Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman
Journal:  Schizophr Res       Date:  2018-08-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.